Cardiol Therapeutics Class Stock Price Prediction
| CRDL Stock | USD 1.62 0.04 2.53% |
Oversold Vs Overbought
43
Oversold | Overbought |
EPS Estimate Next Quarter (0.11) | EPS Estimate Current Year (0.41) | EPS Estimate Next Year (0.38) | Wall Street Target Price 12.4228 | EPS Estimate Current Quarter (0.11) |
Using Cardiol Therapeutics hype-based prediction, you can estimate the value of Cardiol Therapeutics Class from the perspective of Cardiol Therapeutics response to recently generated media hype and the effects of current headlines on its competitors.
The fear of missing out, i.e., FOMO, can cause potential investors in Cardiol Therapeutics to buy its stock at a price that has no basis in reality. In that case, they are not buying Cardiol because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Cardiol Therapeutics after-hype prediction price | USD 1.63 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Cardiol |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Cardiol Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Cardiol Therapeutics After-Hype Price Prediction Density Analysis
As far as predicting the price of Cardiol Therapeutics at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Cardiol Therapeutics or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Cardiol Therapeutics, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Cardiol Therapeutics Estimiated After-Hype Price Volatility
In the context of predicting Cardiol Therapeutics' stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Cardiol Therapeutics' historical news coverage. Cardiol Therapeutics' after-hype downside and upside margins for the prediction period are 0.08 and 5.43, respectively. We have considered Cardiol Therapeutics' daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Cardiol Therapeutics is very risky at this time. Analysis and calculation of next after-hype price of Cardiol Therapeutics is based on 3 months time horizon.
Cardiol Therapeutics Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Cardiol Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cardiol Therapeutics backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Cardiol Therapeutics, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.22 | 3.80 | 0.05 | 0.38 | 6 Events / Month | 2 Events / Month | In about 6 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
1.62 | 1.63 | 3.16 |
|
Cardiol Therapeutics Hype Timeline
Cardiol Therapeutics is currently traded for 1.62. The entity has historical hype elasticity of 0.05, and average elasticity to hype of competition of 0.38. Cardiol is forecasted to increase in value after the next headline, with the price projected to jump to 1.63 or above. The average volatility of media hype impact on the company the price is over 100%. The price upswing on the next news is projected to be 3.16%, whereas the daily expected return is currently at -0.22%. The volatility of related hype on Cardiol Therapeutics is about 217.77%, with the expected price after the next announcement by competition of 2.00. Cardiol Therapeutics Class currently holds 174.34 K in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Given the investment horizon of 90 days the next forecasted press release will be in about 6 days. Check out Cardiol Therapeutics Basic Forecasting Models to cross-verify your projections.Cardiol Therapeutics Related Hype Analysis
Having access to credible news sources related to Cardiol Therapeutics' direct competition is more important than ever and may enhance your ability to predict Cardiol Therapeutics' future price movements. Getting to know how Cardiol Therapeutics' peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Cardiol Therapeutics may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| HLN | Haleon plc | 0.04 | 8 per month | 0.00 | (0.17) | 1.25 | (1.40) | 4.56 | |
| ITCI | Intracellular Th | 3.45 | 8 per month | 1.32 | 0.07 | 3.04 | (2.53) | 16.17 |
Cardiol Therapeutics Additional Predictive Modules
Most predictive techniques to examine Cardiol price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Cardiol using various technical indicators. When you analyze Cardiol charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Cardiol Therapeutics Predictive Indicators
The successful prediction of Cardiol Therapeutics stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Cardiol Therapeutics Class, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Cardiol Therapeutics based on analysis of Cardiol Therapeutics hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Cardiol Therapeutics's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Cardiol Therapeutics's related companies. | 2023 | 2024 (projected) | Days Sales Outstanding | 1.7K | 1.5K | PTB Ratio | 2.51 | 2.38 |
Story Coverage note for Cardiol Therapeutics
The number of cover stories for Cardiol Therapeutics depends on current market conditions and Cardiol Therapeutics' risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Cardiol Therapeutics is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Cardiol Therapeutics' long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Cardiol Therapeutics Short Properties
Cardiol Therapeutics' future price predictability will typically decrease when Cardiol Therapeutics' long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Cardiol Therapeutics Class often depends not only on the future outlook of the potential Cardiol Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Cardiol Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 64.5 M | |
| Cash And Short Term Investments | 34.9 M |
Check out Cardiol Therapeutics Basic Forecasting Models to cross-verify your projections. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardiol Therapeutics. If investors know Cardiol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardiol Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.38) | Return On Assets (0.54) | Return On Equity (1.08) |
The market value of Cardiol Therapeutics is measured differently than its book value, which is the value of Cardiol that is recorded on the company's balance sheet. Investors also form their own opinion of Cardiol Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cardiol Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardiol Therapeutics' market value can be influenced by many factors that don't directly affect Cardiol Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cardiol Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardiol Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiol Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.